| Name | Title | Contact Details |
|---|
LTCG is a leading provider of business process outsourcing for the insurance industry. The nations largest insurers rely on our unparalleled expertise to help manage their complex long-term care portfolios and maximize financial performance. We also provide clients with advanced risk management insight built upon our unique and proprietary long-term care underwriting and claims databases. LTCG has more than 1.4 million long-term care policies currently under its management, representing nearly 20% of all active policies. We serve over 50 national carriers, including every one of the top 10 insurers in the long-term care market. Our experienced management team, which has worked together for years, includes some of the most recognized and respected leaders in the long-term care industry. And our information systems have been developed specifically to support the intricacies of this unique market. To learn more, visit www.ltcg.com
Every purpose-driven brand has a story worth sharing. Storykind ensures your message reaches the right audience, at the right time, and in the right way. We turn inertia into action and audiences into advocates—growing your brand for a better, kinder world. Contact us at hello@storykind.com.
Le groupe international Ondura est spécialisé dans les solutions détanchéité pour les bâtiments et regroupe des entreprises leaders dans leurs domaines : Onduline (toiture légère pour les toits en pente), CB (écrans de protection pour façades et de sous-toiture pour toits inclinés) et Alwitra (systèmes détanchéité hautes performances pour les toits plats). Il dispose de 13 usines en France, Allemagne, Pologne, Espagne, Russie, États-Unis, Malaisie, Brésil et Turquie. Il réalise un chiffre daffaires consolidé de 350 M€ dans plus de 100 pays et emploie 2000 personnes de 34 nationalités différentes.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.